Cagrilintide vs MK-677 for appetite
Short answer: For appetite, more users report improvement with Cagrilintide — 100% of 8 reports, versus 66% of 228 for MK-677.
Cagrilintide has 9 meta-analyses and 15 randomized trials on PubMed; MK-677 has 0 and 15.
Based on 32 reports about Cagrilintide and 978 about MK-677. Not medical advice.
| Cagrilintide Peptide | MK-677 Substance | |
|---|---|---|
| Users say it helped | 82%helped11 reports · few reports | 39%helped479 reports · high confidence |
| Verdict | Mostly positive | Mixed |
| Research | AResearch: Strong | BResearch: Moderate |
| Meta-analyses / RCTs | 9 / 15 | 0 / 15 |
| Mainly used for | ||
| Appetite % reporting improvement | 100% (8) | 66% (228) |
| Sleep % reporting improvement | — | 79% (170) |
| Recovery % reporting improvement | — | 99% (106) |
| Performance % reporting improvement | — | 90% (87) |
| Energy % reporting improvement | — | 37% (62) |
| Common side effects | fatigue, appetite loss, depressive episode | water retention, fatigue, stomach issues, hunger |
| Typical dose reported | Not listed | 12.5 mg / before dinner |
GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss. The results prompt safety concerns for GLP-1RAs, especially with high dose administration, regarding gastrointestinal adverse events.
BMJ, 2024 ↗“Cagri was a game changer for me. I added 1mg and thats been more than enough.”
“From my own experience (also have suffered from poor sleep), i experienced a noticeable increase in sleep quality even with a low dose.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate